Association Between Residual Platelet Reactivity on Clopidogrel Treatment and Severity of Coronary Atherosclerosis: Intrinsic Hypercoagulability as a Mediator

Advances in Therapy

Volumn 36, Issue 9, 2019, Pages 2296-2309

  Zhao, Xin ^a   Wu, Hongyi ^a   Xu, Huajie ^a   Shen, Li ^a   Fan, Bing ^a   Ge, Junbo ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

Antiplatelet agents; Clot strength; Fibrinogen; Intrinsic coagulability; Three vessel disease

Indexed keywords

ACETYLSALICYLIC ACID; APOLIPOPROTEIN B; CLOPIDOGREL; FIBRINOGEN; ANTITHROMBOCYTIC AGENT; TICLOPIDINE;

ADULT; ARTICLE; CARDIOVASCULAR RISK; CORONARY ANGIOGRAPHY; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY BYPASS GRAFT; DISEASE SEVERITY; FEMALE; FIBRINOGEN BLOOD LEVEL; HUMAN; HYPERCOAGULABILITY; INTRINSIC HYPERCOAGULABILITY; MAJOR CLINICAL STUDY; MALE; MEDIATOR; MIDDLE AGED; NEUTROPHIL; OBSERVATIONAL STUDY; PERCUTANEOUS CORONARY INTERVENTION; PLATELET REACTIVITY; QUANTITATIVE ANALYSIS; RESIDUAL PLATELET REACTIVITY; RETROSPECTIVE STUDY; THROMBOELASTOGRAPHY; AGED; CORONARY ARTERY DISEASE; DRUG EFFECT; DRUG ELUTING STENT; PROCEDURES; RESTENOSIS; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOPHILIA;

AGED; CLOPIDOGREL; CORONARY ARTERY DISEASE; CORONARY RESTENOSIS; DRUG-ELUTING STENTS; FEMALE; HUMANS; MALE; MIDDLE AGED; PLATELET ACTIVATION; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; RETROSPECTIVE STUDIES; THROMBELASTOGRAPHY; THROMBOPHILIA; TICLOPIDINE;

EID: 85070070953     PISSN: 0741238X     EISSN: 18658652     Source Type: Journal    
DOI: 10.1007/s12325-019-01032-2     Document Type: Article

References (51)

1. Windecker S, Kolh P, Alfonso F, et al. 2014 ESC/EACTS guidelines on myocardial revascularization. EuroIntervention. 2015;10(9):1024–94.
2. Serruys PW, Morice MC, Kappetein AP, et al. Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease. N Engl J Med. 2009;360(10):961–72.
3. Mohr FW, Morice MC, Kappetein AP, et al. Coronary artery bypass graft surgery versus percutaneous coronary intervention in patients with three-vessel disease and left main coronary disease: 5-year follow-up of the randomised, clinical SYNTAX trial. Lancet. 2013;381(9867):629–38.
4. Geisler T, Zurn C, Simonenko R, et al. Early but not late stent thrombosis is influenced by residual platelet aggregation in patients undergoing coronary interventions. Eur Heart J. 2010;31(1):59–66.
5. Stone GW, Witzenbichler B, Weisz G, et al. Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study. Lancet. 2013;382(9892):614–23.
6. Mangiacapra F, de Bruyne B, Muller O, et al. High residual platelet reactivity after clopidogrel: extent of coronary atherosclerosis and periprocedural myocardial infarction in patients with stable angina undergoing percutaneous coronary intervention. JACC Cardiovasc Interv. 2010;3(1):35–40.
7. Chirumamilla AP, Maehara A, Mintz GS, et al. High platelet reactivity on clopidogrel therapy correlates with increased coronary atherosclerosis and calcification: a volumetric intravascular ultrasound study. JACC Cardiovasc Imaging. 2012;5(5):540–9.
8. Redfors B, Ben-Yehuda O, Lin SH, et al. Quantifying ischemic risk after percutaneous coronary intervention attributable to high platelet reactivity on clopidogrel (From the Assessment of Dual Antiplatelet Therapy with Drug-Eluting Stents Study). Am J Cardiol. 2017;120(6):917–23.
9. Gurbel PA, Bliden KP, Navickas IA, et al. Adenosine diphosphate-induced platelet-fibrin clot strength: a new thrombelastographic indicator of long-term poststenting ischemic events. Am Heart J. 2010;160(2):346–54.
10. Gurbel PA, Bliden KP, Guyer K, et al. Platelet reactivity in patients and recurrent events post-stenting: results of the PREPARE POST-STENTING Study. J Am Coll Cardiol. 2005;46(10):1820–6.
11. Jeong YH, Bliden KP, Shuldiner AR, et al. Thrombin-induced platelet-fibrin clot strength: relation to high on-clopidogrel platelet reactivity, genotype, and post-percutaneous coronary intervention outcomes. Thromb Haemost. 2014;111(4):713–24.
12. Gremmel T, Kopp CW, Seidinger D, et al. Preserved thrombin-inducible platelet activation in thienopyridine-treated patients. Eur J Clin Invest. 2013;43(7):689–97.
13. Mahmud E, Cavendish JJ, Tsimikas S, et al. Elevated plasma fibrinogen level predicts suboptimal response to therapy with both single- and double-bolus eptifibatide during percutaneous coronary intervention. J Am Coll Cardiol. 2007;49(22):2163–71.
14. Anand SS, Yusuf S. Oral anticoagulants in patients with coronary artery disease. J Am Coll Cardiol. 2003;41(4 Suppl S):62S–9S.
15. Mega JL, Braunwald E, Wiviott SD, et al. Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med. 2012;366(1):9–19.
16. Ohman EM, Roe MT, Steg PG, et al. Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind, multicentre, randomised trial. Lancet. 2017;389(10081):1799–808.
17. Eikelboom JW, Connolly SJ, Bosch J, et al. Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease. N Engl J Med. 2017;377:1319–30.
18. Fihn SD, Blankenship JC, Alexander KP, et al. 2014 ACC/AHA/AATS/PCNA/SCAI/STS focused update of the guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines, and the American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol. 2014;64(18):1929–49.
19. Roffi M, Patrono C, Collet JP, et al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). Eur Heart J. 2016;37(3):267–315.
20. IBANEZ B, JAMES S, AGEWALL S, et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J, 2017.
21. Tantry US, Bonello L, Aradi D, et al. Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding. J Am Coll Cardiol. 2013;62(24):2261–73.
22. Hayes AF, Rockwood NJ. Regression-based statistical mediation and moderation analysis in clinical research: observations, recommendations, and implementation. Behav Res Ther. 2017;98:39–57.
23. Zhang Y, Zhu CG, Guo YL, et al. Fibrinogen and the severity of coronary atherosclerosis among adults with and without statin treatment: lipid as a mediator. Heart Lung Circ. 2016;25(6):558–67.
24. Albert JM. Mediation analysis via potential outcomes models. Stat Med. 2008;27(8):1282–304.
25. Tantry US, Bliden KP, Suarez TA, et al. Hypercoagulability, platelet function, inflammation and coronary artery disease acuity: results of the Thrombotic Risk Progression (TRIP) study. Platelets. 2010;21(5):360–7.
26. Lippi G, Franchini M, Targher G. Arterial thrombus formation in cardiovascular disease. Nat Rev Cardiol. 2011;8(9):502–12.
27. Escaned J, Collet C, Ryan N, et al. Clinical outcomes of state-of-the-art percutaneous coronary revascularization in patients with de novo three vessel disease: 1-year results of the SYNTAX II study. Eur Heart J. 2017;38(42):3124–34.
28. Farooq V, van Klaveren D, Steyerberg EW, et al. Anatomical and clinical characteristics to guide decision making between coronary artery bypass surgery and percutaneous coronary intervention for individual patients: development and validation of SYNTAX score II. Lancet. 2013;381(9867):639–50.
29. Rivard GE, Brummel-Ziedins KE, Mann KG, et al. Evaluation of the profile of thrombin generation during the process of whole blood clotting as assessed by thrombelastography. J Thromb Haemost. 2005;3(9):2039–43.
30. Swiger KJ, Yousuf O, Bliden KP, et al. Cigarette smoking and clopidogrel interaction. Curr Cardiol Rep. 2013;15(5):361.
31. Bonello L, Tantry US, Marcucci R, et al. Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate. J Am Coll Cardiol. 2010;56(12):919–33.
32. Stuckey TD, Kirtane AJ, Brodie BR, et al. Impact of aspirin and clopidogrel hyporesponsiveness in patients treated with drug-eluting stents: 2-year results of a prospective, multicenter registry study. JACC Cardiovasc Interv. 2017;10(16):1607–17.
33. Trenk D, Stone GW, Gawaz M, et al. A randomized trial of prasugrel versus clopidogrel in patients with high platelet reactivity on clopidogrel after elective percutaneous coronary intervention with implantation of drug-eluting stents: results of the TRIGGER-PCI (Testing Platelet Reactivity In Patients Undergoing Elective Stent Placement on Clopidogrel to Guide Alternative Therapy With Prasugrel) study. J Am Coll Cardiol. 2012;59(24):2159–64.
34. Collet JP, Cuisset T, Range G, et al. Bedside monitoring to adjust antiplatelet therapy for coronary stenting. N Engl J Med. 2012;367(22):2100–9.
35. Price MJ, Berger PB, Teirstein PS, et al. Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. JAMA. 2011;305(11):1097–105.
36. Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007;357(20):2001–15.
37. Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009;361(11):1045–57.
38. Valgimigli M, Bueno H, Byrne RA et al. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2017.
39. Gurbel PA, Tantry US. GEMINI-ACS-1: toward unearthing the antithrombotic therapy cornerstone for acute coronary syndromes. Lancet. 2017;389(10081):1773–5.
40. Esmon CT. Targeting factor Xa and thrombin: impact on coagulation and beyond. Thromb Haemost. 2014;111(4):625–33.
41. Wu H, Qian J, Wang Q, et al. Thrombin induced platelet–fibrin clot strength measured by thrombelastography is a novel marker of platelet activation in acute myocardial infarction. Int J Cardiol. 2014;172(1):e24–5.
42. Woodward M, Lowe GD, Francis LM, et al. A randomized comparison of the effects of aspirin and clopidogrel on thrombotic risk factors and C-reactive protein following myocardial infarction: the CADET trial. J Thromb Haemost. 2004;2(11):1934–40.
43. Ndrepepa G, Braun S, King L, et al. Relation of fibrinogen level with cardiovascular events in patients with coronary artery disease. Am J Cardiol. 2013;111(6):804–10.
44. Zhang Y, Zhu C, Guo Y, et al. Higher fibrinogen level is independently linked with the presence and severity of new-onset coronary atherosclerosis among han Chinese population. PLoS ONE. 2014;9(11):e113460.
45. Ang L, Thani KB, Ilapakurti M, et al. Elevated plasma fibrinogen rather than residual platelet reactivity after clopidogrel pre-treatment is associated with an increased ischemic risk during elective percutaneous coronary intervention. J Am Coll Cardiol. 2013;61(1):23–34.
46. Lv HC, Wu HY, Yin JS, et al. Thrombin induced platelet-fibrin clot strength in relation to platelet volume indices and inflammatory markers in patients with coronary artery disease. Oncotarget. 2017;8(38):64217–23.
47. Cheung MWL. Comparison of approaches to constructing confidence intervals for mediating effects using structural equation models. Struct Equ Model. 2007;14:227–46.
48. Kaptoge S, di Angelantonio E, Pennells L, et al. C-reactive protein, fibrinogen, and cardiovascular disease prediction. N Engl J Med. 2012;367(14):1310–20.
49. Marianne TS, Kim O, Søren PJ, et al. Genetic susceptibility, smoking, obesity and risk of venous thromboembolism. Br J Haematol. 2010;149:273–9.
50. Peverill RE, Teede HJ, Malan E, et al. Relationship of waist and hip circumference with coagulation and fibrinolysis in postmenopausal women. Clin Sci. 2007;113(9):383–91.
51. ®) in obese patients. Thromb Res. 2015;135:548–53.